Trading opportunity – RTTR– don’t miss it. As usual – risky hence play it with guts.
Shares Outstanding 11.62M
% Held by Insiders 30.71%
% Held by Institutions 25.80%
Shares Short 564920
(source – yahoo finance)
Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial
Ritter Pharmaceuticals, Inc. ( NASDAQ : RTTR ) announced on March 28th, 2017 topline findings from its Phase 2b/3 study designed to evaluate RP-G28 in subjects with lactose intolerance. Results from the 377-subject trial show a clinically meaningful benefit to subjects in the reduction of lactose intolerance symptoms across a variety of outcome measures. The majority of analyses showed positive outcome measures and the robustness of the data point to a clear drug effect. Based on these trial results, the Company believes that the successful completion of a confirmatory Phase 3 program could be adequate to support a New Drug Application (NDA) submission and therefore has requested an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).